192 results
Page 4 of 10
8-K
EX-99.1
lt73cc3xqtzf9cao
1 Dec 14
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
12:00am
8-K
EX-10.3
8kx8d
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.5
8g8xd4h
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.1
fffvli 2irv0lm544iiu
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.4
iuwyny13
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am
8-K
EX-10.8
s6l9wx3ojxrw2
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.7
zmne60s
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.1
g2w xam4md5iki61dh2
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.4
6o8wlz kv9ovy
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
8-K
EX-10.5
cxxqc9ezp
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am